AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16095415 — intervention group
Group type: COMPARATOR
Intervention: Sea Level Control (SLC) condition (P(I)o(2) = 147.3 mm Hg)
Number of subjects: 20
Study 16095415 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude (AL) condition
Number of subjects: 20
Study 16095415 — intervention group
Group type: COMPARATOR
Intervention: Sea Level Control (SLC) condition
Number of subjects: 20
Study 12584827 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangxian Baogan Decoction (KXBGD)
Number of subjects: 81
Study 12584827 — intervention group
Group type: COMPARATOR
Intervention: Conventional liver protecting treatment
Number of subjects: 81
Study 10512280 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL epidural saline flush
Number of subjects: 8
Study 10512280 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL epidural saline flush
Number of subjects: 8
Study 10512280 — intervention group
Group type: COMPARATOR
Intervention: Control (no saline flush)
Number of subjects: 8
Study 10512280 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 8
Study 8545555 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous training
Number of subjects: 53
Study 8545555 — intervention group
Group type: COMPARATOR
Intervention: Analogic Erickson's techniques
Number of subjects: 53
Study 8386751 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus carboplatin (EC)
Number of subjects: 270
Study 8386751 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 270
Study 3510285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose metoclopramide
Number of subjects: 66
Study 3510285 — intervention group
Group type: COMPARATOR
Intervention: Intravenous high-dose metoclopramide
Number of subjects: 66
Study 29482677 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication application (app)
Number of subjects: 40
Study 29482677 — intervention group
Group type: COMPARATOR
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 40
Study 27452837 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over the left temporo-parietal junction (TPJ)
Number of subjects: 42
Study 27452837 — intervention group
Group type: COMPARATOR
Intervention: Sham anodal tDCS over the left temporo-parietal junction (TPJ)
Number of subjects: 42
Study 27452837 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cathodal tDCS over the left prefrontal cortex (PFC)
Number of subjects: 42
Study 27452837 — intervention group
Group type: COMPARATOR
Intervention: Sham cathodal tDCS over the left prefrontal cortex (PFC)
Number of subjects: 42
Study 26629666 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional training for nurses
Number of subjects: 17
Study 26629666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no professional training)
Number of subjects: 17
Study 23216231 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet
Number of subjects: 21
Study 21689029 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser
Number of subjects: 2
Study 21689029 — intervention group
Group type: COMPARATOR
Intervention: 1064-nm Nd:YAG laser
Number of subjects: 2
Study 19134274 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance group (HCTZ + spironolactone or captopril)
Number of subjects: 853
Study 19134274 — intervention group
Group type: COMPARATOR
Intervention: Non-compliance group (HCTZ + spironolactone or captopril)
Number of subjects: 853
Study 19134274 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance group
Number of subjects: 853
Study 19134274 — intervention group
Group type: COMPARATOR
Intervention: Non-compliance group
Number of subjects: 853
Study 17263269 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml/kg of intravenous isotonic electrolyte solution (0.9% sodium chloride) (group A)
Number of subjects: 200
Study 17263269 — intervention group
Group type: COMPARATOR
Intervention: 2 ml/kg of intravenous isotonic electrolyte solution (0.9% sodium chloride) (group B)
Number of subjects: 200
Study 12671771 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavyweight, rigid polypropylene mesh (group A)
Number of subjects: 40
Study 12671771 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavyweight, softer polypropylene mesh (group B)
Number of subjects: 40
Study 10616846 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW apo(a) phenotypes
Number of subjects: 227
Study 10616846 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with matched apo(a) phenotypes
Number of subjects: 227
Study 10616846 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW apo(a) phenotypes
Number of subjects: 227
Study 7555621 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 62
Study 7555621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2303557 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit group (early sibling visitation during the first week of neonatal life)
Number of subjects: 31
Study 2303557 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (visited only after the study was completed, 3 weeks after birth)
Number of subjects: 31
Study 7250779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2‐alpha gel (2.5 mg, intracervically)
Number of subjects: 581
Study 7250779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 tablets (1 mg, orally)
Number of subjects: 581
Study 7250779 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 581
Study 7250779 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 581
Study 30821167 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, fexofenadine, and fluticasone nasal spray (Mo-Fex-Flu)
Number of subjects: 428
Study 30821167 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine and fluticasone nasal spray (Cet-Flu)
Number of subjects: 428
Study 28125977 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS) for medication review
Number of subjects: 0
Study 28125977 — intervention group
Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 0
Study 26148314 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and impact training
Number of subjects: 51
Study 26148314 — intervention group
Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 51
Study 23702393 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa 0.2 mg/kg every 2 weeks
Number of subjects: 18
Study 23702393 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa 0.1 mg/kg/week
Number of subjects: 18
Study 23702393 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa 0.2 mg/kg/week
Number of subjects: 18
Study 23702393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21658010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) glutamine supplementation, 0.283 g glutamine/kg body weight/24 h for the entire ICU stay
Number of subjects: 413
Study 21658010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 413
Study 19701107 — intervention group
Group type: EXPERIMENTAL
Intervention: Canfosfamide (400-1000 mg/m2 IV) with carboplatin (AUC 6 IV) and paclitaxel (200 mg/m2 IV)
Number of subjects: 129
Study 16735495 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/d
Number of subjects: 140
Study 16735495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 15330905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (3 or 5 million units thrice a week) plus ribavirin (1,000-1,200 mg)
Number of subjects: 56
Study 15330905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (5 million units) plus ribavirin (1,000-1,200 mg)
Number of subjects: 56
Study 15330905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (3 million units) plus ribavirin (1,000-1,200 mg)
Number of subjects: 56
Study 15330905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (higher dose) plus ribavirin (1,000-1,200 mg)
Number of subjects: 56
Study 15330905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b and ribavirin
Number of subjects: 56
Study 10756578 — intervention group
Group type: EXPERIMENTAL
Intervention: Misti Gold II prostheses
Number of subjects: 41
Study 10756578 — intervention group
Group type: COMPARATOR
Intervention: Saline-filled prostheses
Number of subjects: 41
Study 9283926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 82
Study 9283926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 9283926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (in patients with serious physical illness who completed 5 or more weeks)
Number of subjects: 82
Study 7942576 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg dl alpha‐tocopheryl acetate daily for 30 days
Number of subjects: 32
Study 7942576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2465180 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic examination of morning sputum
Number of subjects: 12
Study 2465180 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic examination of 24 h sputum
Number of subjects: 12
Study 2465180 — intervention group
Group type: COMPARATOR
Intervention: Cultural examination of homogenized sputum
Number of subjects: 12
Study 2465180 — intervention group
Group type: COMPARATOR
Intervention: Homogenization with 2% pancreatin
Number of subjects: 12
Study 30921234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger consumption (1600-4000mg daily)
Number of subjects: 454
Study 30921234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ginger consumption)
Number of subjects: 454
Study 28504480 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling (28 patients, one session every 4 weeks)
Number of subjects: 90
Study 28504480 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (34 patients, one session every 2 weeks)
Number of subjects: 90
Study 28504480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of microneedling and platelet-rich plasma (28 patients, alternative sessions every 2 weeks for a maximum of six sessions)
Number of subjects: 90
Study 26271815 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support (structured home visits)
Number of subjects: 442
Study 26271815 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support (structured home visits) among care-naïve participants
Number of subjects: 442
Study 26271815 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 442
Study 26271815 — intervention group
Group type: COMPARATOR
Intervention: Standard of care among care-naïve participants
Number of subjects: 442
Study 23349407 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation plus early ACL reconstruction
Number of subjects: 121
Study 23349407 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation plus optional delayed ACL reconstruction
Number of subjects: 121
Study 21419002 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/d)
Number of subjects: 55
Study 21419002 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiparkinsonian drug therapy alone (Control)
Number of subjects: 55
Study 18211932 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levofloxacin 0.3%
Number of subjects: 48
Study 18211932 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and oral levofloxacin (250 mg)
Number of subjects: 48
Study 18211932 — intervention group
Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3%
Number of subjects: 48
Study 18211932 — intervention group
Group type: COMPARATOR
Intervention: Topical ciprofloxacin 0.3%
Number of subjects: 48
Study 18211932 — intervention group
Group type: COMPARATOR
Intervention: Oral ofloxacin 400 mg
Number of subjects: 48
Study 18211932 — intervention group
Group type: COMPARATOR
Intervention: Oral ciprofloxacin 400 mg
Number of subjects: 48
Study 18211932 — intervention group
Group type: COMPARATOR
Intervention: Oral levofloxacin 250 mg
Number of subjects: 48
Study 16570297 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylphenidate (0.8 mg/kg)
Number of subjects: 11
Study 16570297 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 11
Study 14610980 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge Enhances Your Safety (KEYS) curriculum
Number of subjects: 0
Study 10731187 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol or stanol margarines (2 g added to an average daily portion)
Number of subjects: 0
Study 10731187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in low density lipoprotein cholesterol
Number of subjects: 0
Study 8632939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pavement stencil intervention group
Number of subjects: 319
Study 8632939 — intervention group
Group type: COMPARATOR
Intervention: Education-only group
Number of subjects: 319
Study 1534771 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative laparoscopy
Number of subjects: 63
Study 1534771 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 63
Study 3937510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg tablet, twice daily)
Number of subjects: 177
Study 3937510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 3937510 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 177
Study 30624586 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril and 0.8 mg folic acid
Number of subjects: 620
Study 30624586 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril alone
Number of subjects: 620
Study 30624586 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma retinol (per 10-μg/dL increment)
Number of subjects: 620
Study 30252845 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT)
Number of subjects: 24
Study 30252845 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 24
Study 26507194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150/175 μg)
Number of subjects: 18
Study 26507194 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (1.2 mg)
Number of subjects: 18
Study 26507194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24060350 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced standard treatment plus a Web‐based psychosocial intervention (Therapeutic Education System - TES)
Number of subjects: 160
Study 24060350 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 160
Study 22038880 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises associated with pelvic floor muscle training (HE + PFMT)
Number of subjects: 58
Study 22038880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 58
Study 22038880 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 20638338 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (traditional Chinese medicine)
Number of subjects: 635
Study 20638338 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (validated placebo needle)
Number of subjects: 635
Study 17975152 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel every three weeks
Number of subjects: 1006
Study 17975152 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel weekly
Number of subjects: 1006
Study 17975152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 1006
Study 15844060 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream (Aldara; 3M Pharmaceuticals)
Number of subjects: 40
Study 15844060 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 40
Study 11973192 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion
Number of subjects: 54
Study 10392063 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% IPAA (Nutrineal, Baxter Healthcare Ltd) administered once per day for 18 weeks
Number of subjects: 1
Study 7658090 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 30
Study 7658090 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 30
Study 2663834 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol, 0.25 to 4.0 mg/day (M = 0.844) for 4 weeks
Number of subjects: 45
Study 2663834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1095996 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine esterified estrogen
Number of subjects: 0
Study 1095996 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic esterfield estrogens
Number of subjects: 0
Study 1095996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no estrogen therapy)
Number of subjects: 0
Study 30763426 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cytoreductive nephrectomy
Number of subjects: 0
Study 30763426 — intervention group
Group type: COMPARATOR
Intervention: Deferred cytoreductive nephrectomy
Number of subjects: 0
Study 29200840 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 μg
Number of subjects: 1152
Study 29200840 — intervention group
Group type: COMPARATOR
Intervention: tiotropium 5 μg
Number of subjects: 1152
Study 29200840 — intervention group
Group type: COMPARATOR
Intervention: olodaterol 5 μg
Number of subjects: 1152
Study 26431648 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic nursing combined with conventional therapy (test group I)
Number of subjects: 90
Study 26431648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-driving and atomized Mucosolvan inhalation combined with holistic nursing (test group II)
Number of subjects: 90
Study 26431648 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 90
Study 24103895 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine (rHPIV3cp45)
Number of subjects: 40
Study 24103895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21576828 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (atenolol, 25-50mg/day, n=60)
Number of subjects: 120
Study 21576828 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists (benidipine, 4-8 mg/day, n=60)
Number of subjects: 120
Study 18801626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support programme for community pharmacies to send discontinuation letters to patients.
Number of subjects: 90
Study 18801626 — intervention group
Group type: COMPARATOR
Intervention: Control group with a written manual for pharmacies.
Number of subjects: 90
Study 17397739 — intervention group
Group type: EXPERIMENTAL
Intervention: Zernike treatment tables
Number of subjects: 32
Study 17397739 — intervention group
Group type: COMPARATOR
Intervention: Fourier treatment tables
Number of subjects: 32
Study 14671236 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose/potassium/insulin (GKI) infusions
Number of subjects: 0
Study 14671236 — intervention group
Group type: COMPARATOR
Intervention: Saline infusions (control)
Number of subjects: 0
Study 11317693 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 autoantibodies (p53‐Ab) detected in serum
Number of subjects: 130
Study 11317693 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 autoantibodies (p53‐Ab)
Number of subjects: 130
Study 9399737 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol 0.1 mg/day
Number of subjects: 20
Study 9399737 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 0.1 mg and medroxyprogesterone acetate 2.5 mg/day
Number of subjects: 20
Study 7956276 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (150 mg/kg IV over 15 mins, then 12.5 mg/hr continuous infusion for 90 mins)
Number of subjects: 58
Study 7956276 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (entire group)
Number of subjects: 58
Study 7956276 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine responders
Number of subjects: 58
Study 7956276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 3294946 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of 8‐methoxypsoralen
Number of subjects: 0
Study 3294946 — intervention group
Group type: COMPARATOR
Intervention: Crystalline formulation of 8‐methoxypsoralen
Number of subjects: 0
Study 3294946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0
Study 29479974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (120 mg) with fentanyl (20 µg/kg)
Number of subjects: 92
Study 27465597 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated bacterial vaccines (typhoid and enterotoxigenic Escherichia coli)
Number of subjects: 8
Study 27465597 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 8
Study 27465597 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient supplementation
Number of subjects: 8
Study 27465597 — intervention group
Group type: COMPARATOR
Intervention: Rotavirus vaccine
Number of subjects: 8
Study 24996498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-foam sonography (HyFoSy)
Number of subjects: 40
Study 24996498 — intervention group
Group type: COMPARATOR
Intervention: Serial hysterosalpingography (HSG)
Number of subjects: 40
Study 22837377 — intervention group
Group type: EXPERIMENTAL
Intervention: Active continuous positive airway pressure treatment
Number of subjects: 113
Study 22837377 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure treatment
Number of subjects: 113
Study 22837377 — intervention group
Group type: EXPERIMENTAL
Intervention: Active continuous positive airway pressure treatment (crossover phase)
Number of subjects: 113
Study 20724565 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE; α(1))
Number of subjects: 19
Study 20724565 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CL; α(2))
Number of subjects: 19
Study 18450845 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal steroids > 7 days before delivery (remote group)
Number of subjects: 56